On May 28, the website of the Chinese Center for Disease Control and Prevention published the "General Information on Adverse Reaction Monitoring of COVID-19 Vaccine Vaccination" jointly published by the center and the National Adverse Drug Reaction Monitoring Center.

The average annual growth rate from 2010 to 2020 is 0.53%, which is 0.04 percentage points lower than the 0.57% in 2000-2010.

On the evening of May 25, China Securities Regulatory Commission (CSRC) announced that the listing committee of science and technology innovation board approved the IPO application of Vazyme Biotech Co., Ltd.

China has worked together with other countries in the world to overcome difficulties and contribute wisdom and strength to the global epidemic.

On May 12th, Sansure Biotech Inc. issued an announcement that Sansure Biotech will purchase 95,863,038 shares of Shanghai Kehua Bio-Engineering Co., Ltd. (accounting for 18.63% of Kehua's total share capital) held by Gree DC through agreement.

On May 17, 2021, Shenzhen YHLO Biotech Co., Ltd. was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

On May 16, Mindray Medical announced that it intends to acquire 100% of the equity of HytestInvest Oy in Finland and its subsidiaries.

The COVID-19 mRNA vaccine co-developed by German-based BioNTech and China's Fosun Pharma can be rolled out in the Chinese mainland very quickly once it receives authorization, as key steps for mass production are close to ready.

On May 11, BioPerfectus officially announced that their COVID-19 test kit for B.1.617 has been successfully developed.

On May 10th , BGI announced that NUPCO of the Kingdom of Saudi Arabia had recently added a further $38,176,076 to the contract.

On May 10, 2021, Hong Tan, CEO of ET Healthcare, announced that Access Medical Systems (AMS), the parent company of ET Healthcare, has closed a new round of financing in a deal worth more than $100 million.

BioMérieux said on Tuesday that its first quarter 2021 revenues grew approximately 10 percent year over year. The firm also lowered its full-year sales guidance due to uncertainties in the business environment.

Danaher reported on Thursday a 58 percent year over year increase in total revenues driven by its Life Sciences revenues, which more than doubled.

Abbott announced before the market opened on Tuesday that its first quarter Diagnostics business revenues climbed 120 percent year over year.

Roche on Wednesday said its diagnostics sales during the first quarter 2021 grew 50 percent year over year, in part on demand for the company's COVID-19 products.